Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3 No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3 Patients currently being evaluated for Cohort 4 eligibility…